Trial Profile
A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne-Lucentis Combination Therapies and Lucentis Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary) ; Dexamethasone; Ranibizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RADICAL
- Sponsors QLT
- 26 Apr 2014 New trial record